Exact Imaging Receives Frost & Sullivan’s 2019 Imaging Technology Innovation Award

Jennifer Schram Exact Imaging, Main Page, Portfolio News, Press Release

Exact Imaging wins Frost & Sullivan 2019 Diagnostic Imaging Technology Innovation Award

TORONTO, CANADA — Exact Imaging, the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, is the proud recipient of Frost & Sullivan’s 2019 Global Prostate Cancer Diagnostic Imaging Technology Innovation Award.

“Exact Imaging’s 29 MHz micro-ultrasound system, ExactVu, offers a novel approach for targeted real-time biopsies as compared to conventional transrectal ultrasound,” says Durga Chandrupatla, Senior Research Analyst, Transformational Health at Frost & Sullivan. “Moreover, Exact Imaging offers healthcare providers with technical and financial freedom through attributes such as being a bed-side procedure, minimal hands-on experience required, low capital investments, and independence from mpMRI for prostate biopsy, thereby enhancing the overall unique selling proposition of its flagship ExactVuTM micro-ultrasound system.”

“We are proud to have our ExactVu micro-ultrasound platform be recognized as a truly transformational technology in the prostate cancer marketplace by Frost & Sullivan,” says Randy AuCoin, Exact Imaging’s President and CEO. “This is further validation of the significant value that our ExactVu™ micro-ultrasound platform is bringing to urologists globally. The ExactVu™ system provides clinicians with the highest real-time resolution for an imaging system that they can utilize in their clinics for performing targeted prostate biopsies quickly, effectively and across the prostate cancer pathway – from the first biopsy to repeat biopsies and through to active surveillance monitoring. The goal is to provide the most powerful and cost-effective imaging platform that enables urologists to ultimately improve both the standard of care and patient outcomes.”

The Frost & Sullivan Innovation Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

This is the second award in less than a year for Exact Imaging, who also received the 2019 Life Science Company of the Year Award from Life Science Ontario (LSO) in November 2018.

“Exact Imaging is redefining the diagnosis of prostate cancer by driving significant benefits for patients, clinicians and the healthcare system globally”, said LSO President and CEO Dr. Jason Field.  “They are an excellent example of how Ontario-based innovation, coupled with manufacturing and commercialization expertise is fostering world-class medical device companies. We are proud to have chosen Exact Imaging as our 2019 Life Science Company of the Year and look forward to watching their continued growth in the global marketplace”.

About Exact Imaging

Exact Imaging is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. For those cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates fast, simple MRI fusion-based targeting with the guidance of the micro-ultrasound system’s 70-micron real-time resolution. The ExactVu micro-ultrasound system including the FusionVu application has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)), and Canada (Health Canada medical device license). 

About Life Sciences Ontario:

Life Sciences Ontario (LSO) is a member-driven organization that represents and promotes the province’s vibrant and diverse life sciences sector. LSO collaborates with governments, academia, industry, and other life science organizations in Ontario and across Canada to promote and encourage commercial success throughout the sector. Membership in Life Sciences Ontario includes individuals, students, emerging companies, investors, service providers, and companies with marketed products. The organization provides a wide range of networking and educational events, and operates a mentorship program that is helping to develop highly-skilled talent and build new business opportunities for the life sciences sector. LSO is an effective conduit for delivering policy options to governments, and is dedicated to promoting Ontario’s life sciences sector internationally.

For further information, please contact:

Randy AuCoin
President & CEO
Exact Imaging
T. +1.705.927.0512
E. raucoin@exactimaging.com

Related Article: A Comparison of Micro-Ultrasound & Multiparametric MRI Imaging for Prostate Cancer: An International Meta-Analysis